AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00075803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Voriconazole will be administered orally twice daily. Voriconazole capsules should be taken at least one hour before or one hour after a meal. Taken concomitantly with food, bioavailability of voriconazole is reduced. If oral drug is not possible, it will be given intravenously at a dosage of 200 mg every 12 hours over two hours in patients > 12 years. Each voriconazole dose will be diluted to a total volume of 200 mL in patients > 12 years. Volumes of the formulation required to provide 4 mg/kg doses for children age \< 12 years.
Study NCT01743274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCT
Description: Optical Coherence Tomography (OCT) is a recent imaging modality that yields cross-sectional images with a resolution 10 times greater than that of intravascular ultrasound (IVUS). OCT uses a near-infra-red light source to obtain images of the interior walls of the coronary arteries and is increasingly used to evaluate vulnerable atherosclerotic plaques and assess placement and response to stenting.~OCT images are acquired by automated pullback over 2 to 3 seconds of the light source that yields a helicoidal image of a longitudinal segment of 50 mm. Intravascular imaging is obtained by injecting contrast medium or saline solution.
Study NCT02006043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib 150mg
Study NCT04578028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2808
Description: Investigational drug
Study NCT04578028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug
Study NCT01134211 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: nelfilcon A
Description: Commercially marketed, single-vision, soft contact lens for daily disposable wear
Study NCT01386645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high glycemic index diet plus N-acetylcysteine
Description: Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index >70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
Study NCT00484328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: different dosing regimes of Ribavirin
Study NCT02410200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Study NCT04250259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets of placebo in the morning before breakfast and one tablet of placebo in the evening before dinner for 24 months
Study NCT04250259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAMe 400 mg tablet
Description: SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months
Study NCT04257461 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: Bichemotherapy: Oxaliplatine combined with Fluoropyrimidine.
Study NCT01134211 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: filcon II 3
Description: Commercially marketed, single-vision, soft contact lens for daily disposable wear
Study NCT02521519 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medial branch block in one side
Description: MBB: Using sterile conditions, 25G needles will be placed in the desired position. In its final position for the L3 and L4 vertebrae the needle tip should reside at the junction of the superior articular process and the transverse process. At the L5-S1 level the needle tip should reach the junction between the sacral ala and the superior articular process of S1. Following a negative aspiration 0.5ml of injectate will be injected into each site.
Study NCT02521519 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: paravertebral deep intramuscular (PDI) injection
Description: injections will target the deep para-spinal muscles between the spinous process and inter-pedicular line of the L3-5 vertebrae. Under fluoroscopic guidance, a 25-gauge needle will be advanced, directed towards the lamina at the mid-distance between inter-pedicular line and the spinous process of the L3, L4 and L5 vertebrae, until touching the bone. A straight forceps will be attached to the junction of the skin and the needle; the needle will then be withdrawn by 1.4cm, to reside inside the muscle bulk. A five ml syringe diameter will be used to point 1.4 cm withdrawal. Following a negative blood aspiration, each level will be injected with 0.5 ml of the injectate.
Study NCT03756649 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: 50 ml will be collected
Study NCT03756649 — intervention group
Intervention type: PROCEDURE
Intervention: Urine Collection
Description: 50 ml will be collected
Study NCT03756649 — intervention group
Intervention type: PROCEDURE
Intervention: Stool Collection
Description: Three 25 ml tubes will be collected
Study NCT04733482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cosmetic care
Study NCT03580720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory threshold loading protocol
Description: Subjects will be instrumented with catheters that measure electrical activity of the diaphragm and transdiaphragmatic pressure. Subjects will perform a stepwise inspiratory threshold loading protocol to induce a wide range of diaphragm activity.
Study NCT05609058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dedicated treatment board with no degree
Description: the patients were placed in the prone position on a dedicated treatment board with no degree incline using an arm support (with both arms above the head). Te board contained an open aperture on one side to allow for the ipsilateral breast to hang freely away from the chest wall
Study NCT02018315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Triheptanoin is a 7-carbon medium chain triglyceride
Study NCT01473511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strongest Families Intervention (formerly Family Help)
Description: Distance HEALTH education intervention focussed on skill learning for parents
Study NCT04595695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transparent mask
Description: A transparent mask worn by the surgeons in customary fashion will be used.
Study NCT04595695 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Typical surgical covered mask
Description: A standard covered surgical mask worn by the surgeons in in customary fashion will be used.
Study NCT01725997 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hook plate
Description: Surgery with hook plate followed by physiotherapy
Study NCT01725997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Patients will be following a program specific for AC joint dislocations
Study NCT03073005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based Mastery Learning (SBML)
Description: The SBML training group will first 1) watch the VAD video, then 2) participate in a SBML intervention using the simulator for a) driveline exit site sterile dressing changes; b) performing controller self-tests; c) changing power sources; d) troubleshooting emergent VAD-related malfunction; and e) recognizing specific signs and symptoms requiring immediate contact with the VAD team.
Study NCT00720083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Given IV
Study NCT00720083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00720083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: Given orally
Study NCT00720083 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Patients undergo radiotherapy 5 times a week for up to 6.5 weeks.
Study NCT00720083 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiotherapy 5 times a week for up to 6.5 weeks.
Study NCT01489826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol
Description: Patients will (initially) be given a slow intravenous (i.v.) infusion of Dexanabinol over 3 hours on Days 1, 8 and 15 of a three weekly (21 day) cycle.
Study NCT01489826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cremophor
Description: Drug vehicle.
Study NCT03049397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Complete Enhancing Connections program
Study NCT03049397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03539198 — intervention group
Intervention type: RADIATION
Intervention: Proton Stereotactic Body Radiation Therapy (SBRT) (5 fractions; 3500-4500 cGy)
Description: Patients will be receiving proton SBRT
Study NCT03539198 — intervention group
Intervention type: RADIATION
Intervention: Proton Stereotactic Body Radiation Therapy (SBRT) (3-5 fractions; various dose and fractionation regimens depending on treatment site).
Description: Patients will receive proton SBRT.
Study NCT03539198 — intervention group
Intervention type: DRUG
Intervention: Nivolumab 3 mg/kg IV q2 weeks
Description: Patients will receive Nivolumab x2 cycles before SBRT q2 weeks, and continued q2 weeks after SBRT until progression or at the discretion of the treating physician.
Study NCT03539198 — intervention group
Intervention type: RADIATION
Intervention: Proton or Photon SBRT (3-5 fractions; various dose and fractionation regimens depending on treatment site).
Description: Patients with further oligoprogression (5 or fewer sites) will be eligible to receive additional SBRT to all sites of oligoprogression.
Study NCT03432039 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: This intervention has three phases occurring the same time as the Psychoeducation intervention. Phase I provides verbal and written information about the paediatric acute care unit services and policies. Phase II consists of: (a) verbal and written information about the general paediatric unit and its policies, and (b) a parent-child activity having ''control'' activities like reading a story not related to hospital stay. Phase III of the control program consists of a telephone call 2-3 days after discharge during which time mothers were informed that they should contact their primary healthcare providers if their children were having any problems or unusual symptoms. They also were asked to comment on their children's hospital stays during this telephone call.
Study NCT03432039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: This is an educational-behavioural intervention that educates the parent about the children's likely emotional and behavioural problems that may result from ICU admission. Phase I will be delivered within 6 to 16 hours of admission to the hospital where caregivers are provided with information about the child's likely emotional reactions during admission in hospital. Phase II will be delivered within 2 to 16 hours of transfer to the general ward and will consist of: (a) verbal and written information to reinforce information provided in Phase I and (b) a parent-child skills building activities. Phase III of the COPE intervention program will occur 2 to 3 days after hospital discharge and will consist of a telephone call during which a 5 minute script will be read that reinforces young children's typical post-discharge emotions and behaviours and parenting behaviours which would continue to facilitate positive coping outcomes in their children.
Study NCT02622139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: MSOT for the evaluation of disease activity in IBD patients
Study NCT04374617 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex ultrasound and Computed Tomography Angiography
Description: All venous thromboembolisms suspected will diagnosed with ultrasound and CT-angiography
Study NCT01899495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High sodium diet and low sodium diet
Description: Isocaloric diet with 60 mEq of potassium and 1gm protein/kg body weight with high sodium 300mEq; low sodium 10 mEq.
Study NCT02062190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: resveratrol
Description: 100mg 2x/day~1 month
Study NCT02062190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: resveratrol
Description: 100mg 2x/day~1 month
Study NCT00633867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath
Description: Tracheal intubation, using Mcgrath video-laryngoscope
Study NCT00633867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation using Macintosh Laryngoscope
Description: Tracheal intubation using Macintosh Laryngoscope
Study NCT05313919 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive functional diagnostics of coronary circulation
Description: Comprehensive functional diagnostics of coronary circulation in patients with INOCA (ischemia and no obstructive coronary arteries) including:~* echocardiography with assessment of diastolic function~* flow-mediated dilation of brachial artery~* coronary angiography~* functional coronary assessment (RFR, FFR, IMR, CFR, dp/dt, Tau)~* provocative test with acetylcholine (registration of symptoms, ECG and angiographic spasm)~* laboratory tests (full blood count, serum creatinine level, eGFR, lipidogram, serum CRP/hsCRP level, serum NT-proBNP level)~* serum level of inflammatory cytokines and chemokines
Study NCT02615925 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Psychiatry Consultation
Description: Psychiatry Consultation
Study NCT03486704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face to Face VRRS and telerehabilitation
Description: Face to Face cognitive training using VRRS plus telerehabilitation. Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Cognitive training will initially be tailored to the patient's baseline characteristics. The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.~The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program).
Study NCT03486704 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual rehabilitation program
Description: The usual rehabilitation group will receive 12 sessions of face-to-face usual cognitive training program.
Study NCT03486704 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FTF VRRS plus unstructured CS
Description: Face to Face cognitive training using VRRS plus at-home unstructured cognitive stimulation.~Participants will receive 12 sessions of an individualized Face to Face (FTF) cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based unstructured cognitive stimulation (CS), three sessions for week.
Study NCT03486704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face to Face VRRS plus active tDCS and telerehabilitation
Description: Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Face to Face VRRS cognitive training will initially be tailored to the patient's baseline characteristics.~The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program).
Study NCT03486704 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face to Face VRRS plus placebo tDCS and telerehabilitation
Description: Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with placebo tDCS applied to the dorsolateral prefrontal cortex of the left hemisphere over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Face to Face VRRS cognitive training will initially be tailored to the patient's baseline characteristics.~The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program).
Study NCT04276454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexitouch Plus system
Description: A single treatment for external lymphedema using the FDA-approved Flexitouch Plus device.
Study NCT03714737 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: experimental vaccine
Description: bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)
Study NCT03714737 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive control vaccine 1
Description: bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(WALVAX Biological Co., LTD)
Study NCT03714737 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive control vaccine 2
Description: bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(Royal (Wuxi) Biological Co., LTD)
Study NCT02845518 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging (cMRI)
Description: Right ventricular contouring and indexed aortic flow measurement from cMRI will be performed locally with the dedicated software used in clinical practice by the physicians of each centre. Cardiac index and RVEF will be derived from these measures. MRI interpretation will be performed blind with respect of clinical and RHC data.~A self-administered questionnaire made up of 2 Likert scales will be given to all patients on visits V1, V2 or V3 and V9.~To constitute a biobank for diagnosis and prognosis purposes blood samples will be taken at visits V1, V2 or V3 and V9.
Study NCT03499600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Assessment and CFI
Description: CA and CFI families will participate in the Cultural Formulation Interview prior to their standard intake.
Study NCT03499600 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Assessment
Description: CA families will participate their standard intake procedures.
Study NCT02914106 — intervention group
Intervention type: OTHER
Intervention: Observational Study
Description: Patients were diagnosed for AIS by a certified neurologist at the Emergency Room of the Central Military Hospital. Neurological, cognitive and functional status were determined by NIHSS score, Photo test, Pfeiffer mental status score and by modified Rankin score respectively. A sample of venous blood was withdrawn in the early morning (07 to 09 AM) after assessment of neurological and cognitive status.
Study NCT05661760 — intervention group
Intervention type: BEHAVIORAL
Intervention: interdisciplinary multimodal pain treatment
Description: A combination of physical and psychosocial treatment methods is employed, including Emotional Awareness and Expression Therapy (EAET), Pain Neuroscience Education (PNE), Acceptance and Commitment Therapy (ACT), graded activity, exposure in vivo, and experiential learning through physical training.
Study NCT02367040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (Aliqopa, BAY80-6946)
Description: Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered before rituximab.
Study NCT02367040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Placebo will be administered before rituximab.
Study NCT02367040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab dose 375 mg/m2 body surface weekly during Cycle 1 on Days 1, 8, 15 and 22, and then on Day 1 of Cycles 3, 5, 7 and 9.The solution for IV infusions is obtained after reconstitution of a calculated concentration of 1 to 4 mg/ml rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/ml (0.9%) solution for injection or 5% D-Glucose in water.
Study NCT02367040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab dose 375 mg/m2 body surface weekly during Cycle 1 on Days 1, 8, 15 and 22, and then on Day 1 of Cycles 3, 5, 7 and 9.The solution for IV infusions is obtained after reconstitution of a calculated concentration of 1 to 4 mg/ml rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/ml (0.9%) solution for injection or 5% D-Glucose in water.
Study NCT01534403 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: Epratuzumab 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles (ie, Weeks 0, 1, 2, 3, 12, 13, 14, 15, 24, 25, 26, 27, 36, 37, 38, 39, 48, 49, 50, 51, 60, 61, 62, 63, 72, 73, 74, 75, 84, 85, 86, and 87)